ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,079.04
0.48%
US Tech 100
20,890.00
1.04%
다우존스 지수
44,959.44
0.57%
Bitcoin
96,762.14
0.82%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Ikena Oncology Inc (IKNA) 시세

Ikena Oncology Inc

Ikena Oncology Inc (IKNA)

NASDAQ
1.67
-0.03
( -1.76% )
업데이트: 04:12:19
15분 지연

개인 투자자를 위한 전문가급 도구.

프리미엄

주요 통계 및 세부정보

가격
1.67
매수가
1.67
매도가
1.68
거래량
14,310
1.67 일간 변동폭 1.695
1.22 52주 범위 2.32
market_cap
80.591M
전일 종가
1.70
개장가
1.67
최근 거래 시간
10
@
1.6713
마지막 거래 시간
04:19:10
재정 규모
US$ 24,012
VWAP
1.678
평균 볼륨(3m)
52,624
발행 주식
48,258,111
배당수익률
-
주가수익률
-1.18
주당순이익(EPS)
-1.41
매출
9.16M
순이익
-68.17M

Ikena Oncology Inc 정보

Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD... Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. 더 보기

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
www.ikenaoncology.com
본부
Wilmington, Delaware, USA
설립됨
-
Ikena Oncology Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker IKNA. The last closing price for Ikena Oncology was US$1.70. Over the last year, Ikena Oncology shares have traded in a share price range of US$ 1.22 to US$ 2.32.

Ikena Oncology currently has 48,258,111 shares in issue. The market capitalisation of Ikena Oncology is US$82.04 million. Ikena Oncology has a price to earnings ratio (PE ratio) of -1.18.

IKNA 최신 뉴스

추가 뉴스

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

15 11월 2024
Edgar (US Regulatory)

Ikena Oncology Reports Third Quarter 2024 Financial Results

BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced financial results for the third quarter ended September 30, 2024, and provided...

07 11월 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 11월 2024
Edgar (US Regulatory)

Ikena Oncology Reports Second Quarter 2024 Financial Results

BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced financial results for the second quarter ended June 30, 2024, and provided an...

09 8월 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

09 8월 2024
Edgar (US Regulatory)

Form 8-K - Current report

13 7월 2024
Edgar (US Regulatory)

Form 8-K - Current report

11 6월 2024
Edgar (US Regulatory)

UPDATE – Ikena Oncology Announces Strategic Update

Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million;...

29 5월 2024
GlobeNewswire Inc.

Form 8-K - Current report

29 5월 2024
Edgar (US Regulatory)

Ikena Oncology Announces Strategic Update

Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million;...

29 5월 2024
GlobeNewswire Inc.
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.06-3.468208092491.731.741.67580151.70453624CS
4-0.05-2.906976744191.721.791.66808361.71918288CS
12-0.02-1.183431952661.691.791.66526241.71033506CS
26-0.09-5.113636363641.761.871.61160671.69348256CS
520.2215.17241379311.452.321.222290301.54984513CS
156-10.47-86.243822075812.1416.9491.021697713.65644909CS
260-20.73-92.544642857122.437.611.021659485.91797558CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
CYCNCyclerion Therapeutics Inc
US$ 7.10
(340.99%)
117.01M
SMXSMX Security Matters Public Company
US$ 0.5836
(199.59%)
594.39M
SRMSRM Entertainment Inc
US$ 1.11
(76.16%)
132.93M
CNEYCN Energy Group Inc
US$ 0.5505
(74.43%)
151.12M
HTOOFusion Fuel Green PLC
US$ 0.5284
(66.16%)
270.3M
RLMDRelmada Therapeutics Inc
US$ 0.6426
(-76.80%)
14.46M
MIGIMawson Infrastructure Group Inc
US$ 0.8499
(-55.50%)
11.45M
MONDMondee Holdings Inc
US$ 0.2035
(-31.04%)
2.79M
ORISOriental Rise Holdings Ltd
US$ 8.60
(-28.03%)
539.06k
FGLFounder Group Limited
US$ 3.00
(-26.47%)
9.84M
SMXSMX Security Matters Public Company
US$ 0.5888
(202.26%)
594.63M
SVMHSRIVARU Holding Ltd
US$ 0.0275
(25.00%)
451.1M
HTOOFusion Fuel Green PLC
US$ 0.5397
(69.72%)
270.97M
CNEYCN Energy Group Inc
US$ 0.5505
(74.43%)
157.36M
NVDANVIDIA Corporation
US$ 144.94
(3.34%)
147.19M

IKNA Discussion

게시물 보기
Monksdream Monksdream 2 월 전
IKNA under $2
👍️0
Monksdream Monksdream 4 월 전
IKNA under $2
👍️0
Monksdream Monksdream 5 월 전
IKNA under $2
👍️0
Monksdream Monksdream 5 월 전
IKNA under $2
👍️0
glenn1919 glenn1919 6 월 전
IKNA.....................................https://stockcharts.com/h-sc/ui?s=IKNA&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 9 월 전
IKNA under $2=
👍️0
Monksdream Monksdream 9 월 전
IKNA under $2
👍️0
herbied47 herbied47 1 년 전
$196.9M in cash, cash equivalents, and marketable securities, which it said would support operations well into 2026. $5.40 a share in cash
Market cap 37 million as of now. Price targets still between $8 and $11. Lots of upcoming catalyst Bullish
👍️0
herbied47 herbied47 1 년 전
Way over sold! https://finance.yahoo.com/news/broker-revenue-forecasts-ikena-oncology-100336585.html
👍️0
Tacostocks Tacostocks 1 년 전
It went down, because it didnt have the backing of Money hunt...
👍️0
Money hunt Money hunt 1 년 전
what happened here my short friend
👍️0
Tacostocks Tacostocks 1 년 전
Aged like milk eh
👍️0
AJ Freely AJ Freely 1 년 전
$IKNA - 👆Up 5.2% Pre-Market/ Current Price $5
To Acquire & Merge w/ Pionyr Immunotherapeutics
👍️0
Tartiaboy Tartiaboy 2 년 전
This is a very inactive board, but IKNA is worth keeping an eye on. I currently do not own any but am interested enough to follow it. Right now my biggest interest is in IKNA's new molecule IK-595- the RAF:MEK clamp. They intend to file and IND application in 2H2023. I see very big future potential for IK-595 and want to see how IKNA develops it's early clinical plan.

I am not too familiar with there lead drug so I am neutral regarding it.
👍️0
TrendTrade2016 TrendTrade2016 3 년 전
IKNA look at this beast
👍️0
TrendTrade2016 TrendTrade2016 3 년 전
IKNA monster
👍️0
crudeoil24 crudeoil24 4 년 전
Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), transcription factor in the Hippo signaling pathway. It intends to pursue clinical development of IK-930 across a range of tumor types with known Hippo pathway mutations. Its oncology programs also include extracellular signal-related kinase 5 (ERK5) inhibitor / RAS Signaling Pathway inhibitor program, RAS Pathway discovery programs, Tumor Microenvironment Programs, IK-175, IK-412 and IK-007. The Company is developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. It also has early stage discovery programs in targeted oncology in the RAS pathway.
👍️0

최근 히스토리

NASDAQ
IKNA
Ikena Oncology
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유